[What can anti-VEGF therapy achieve in clinical routine? : Effectiveness of anti-VEGF therapy in patients with macular diseases in clinical routine on 1492 eyes in Austria].
BACKGROUND
The aim of this user observational study was to illustrate the effectiveness of intravitreal operative medication administration (IVOM) in the clinical routine.


METHODS
A monocentric, single arm, prospective study.


METHODS
Included in this study were all patients in whom a macular edema was diagnosed during an ophthalmological examination at the Barmherzigen Brüdern Hospital in Linz from November 2012 to August 2014 and who were treated as outpatients or day clinic patients with IVOM using anti-vascular endothelial growth factor (VEGF). The parameters measured during the clinical routine were as follows: best corrected visual acuity (BCVA) using the early treatment diabetic retinopathy study (ETDRS) chart, central optical coherence tomography (OCT) thickness, diagnosis and possible prior treatment with IVOM. Following diagnosis, the IVOM was administered in 6‑week intervals and a final control with measurement of the named parameters (approximately 19 weeks after diagnosis). If edema was present a further 3‑stage series (19 weeks) was initiated. In the case of a "dry" condition the further controls were performed by a private practitioner and the patient only presented again if macular edema reoccurred. A control of the patients with "dry" results at regular intervals was not planned.


RESULTS
A total of 1492 eyes from 1184 patients with an average age of 75.6 ± 11.3 years were included in the study according to the abovenamed criteria. Choroidal neovascularization (CNV) with age-related macular degeneration (AMD) was diagnosed in 879 eyes and 314 eyes were treated for diabetic macular edema (DME). Of the eyes 122 (8.2%) were affected by branch vein thrombosis (AVT) and 63 (4.2%) from central vein thrombosis (CVT). In 47 (3.2%) eyes macular edema with myopic CNV (mCNV) was detected and 67 eyes (4.5%) were not further classified under "others". In all groups a gain in letters could be achieved in the EDTRS chart even after the first IVOM series: AMD + 3.4, DME + 1.3, AVT + 6.1, CVT + 10.1 and mCNV + 7.0. Patients who were treated with IVOM for the first time showed on average a better response than those previously treated with IVOM.


CONCLUSIONS
As in many other studies our data also underline the necessity for intravitreal injections for treatment of macular edema. Even if a 6‑week interval does not nowadays correspond to the current guidelines, we could achieve a stabilization of vision and do not shy away from comparison with large studies, such as the Marina study. In order to provide the increasing numbers of patients the best treatment in the future, an attempt at targeted implementation of resources must be made and if necessary symptoms which can be conservatively treated should be delegated to the private sector.
Krankenhaus Barmherzige Brüder Linz, Seilerstätte 2, 4020, Linz, Österreich. klaus.wiesinger@bblinz.at.
K
K
Wiesinger
Krankenhaus Barmherzige Brüder Linz, Seilerstätte 2, 4020, Linz, Österreich.
P
P
Reinelt
Krankenhaus Barmherzige Brüder Linz, Seilerstätte 2, 4020, Linz, Österreich.
A
A
Ennemoser
Krankenhaus Barmherzige Brüder Linz, Seilerstätte 2, 4020, Linz, Österreich.
M
M
Edelmayr
Krankenhaus Barmherzige Brüder Linz, Seilerstätte 2, 4020, Linz, Österreich.
U
U
Schönherr
D000368:Aged; D000369:Aged, 80 and over; D001317:Austria; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy*; D003930:Diabetic Retinopathy / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy*; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012170:Retinal Vein Occlusion / Q000175:diagnosis / Q000188:drug therapy*; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity / Q000187:drug effects
C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A
Aflibercept; Age related macular degeneration; Bevacizumab; Intravitreal operative medication administration; Macular edema